FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocolInitiation of Phase 1 trial ...
GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available ...
Building disease literacy through MMRF, IMF, and HealthTree enabled informed partnership with myeloma specialists when standard regimens and an initial trial failed. Telehealth during the pandemic ...
AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates ...
Survivorship is defined as starting on day one of diagnosis, reflecting the immediate shift to coping, planning, and survival-oriented decision-making rather than a post-therapy milestone. Chronic ...
In " Beyond Diagnosis: Multiple Myeloma," Cleveland Clinic hematologist Sandra Mazzoni, DO, and host John Mangels continue ...
The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed ...
"Autologous Stem Cell Transplantation Proven Beneficial for Older Patients with Multiple Myeloma"... 4-Year Survival Rate Up ...
Proprietary TeloView® blood-based TELO-MRD assay detected residual myeloma cells in a higher proportion of matched samples than bone-marrow next-generation flow cytometry in a University of Athens ...
GSK has agreed to acquire full global rights to a potential best-in-class trispecific T-cell engager from Chimagen Biosciences in a transaction worth up to $750 million, expanding the pharmaceutical ...
AbbVie Inc. ABBV on Thursday reported topline outcomes from its Phase 3 CERVINO trial evaluating etentamig, an ...
GSK has continued its drive to bulk up its pipeline, taking global rights to a T-cell engager (TCE) for multiple myeloma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results